NO20033936L - Fremgangsmåter for identifisering av forbindelser for regulering av muskelmasse eller funksjon ved anvendelse avkortikotropinfrigjöringsfaktor-reseptorer - Google Patents
Fremgangsmåter for identifisering av forbindelser for regulering av muskelmasse eller funksjon ved anvendelse avkortikotropinfrigjöringsfaktor-reseptorerInfo
- Publication number
- NO20033936L NO20033936L NO20033936A NO20033936A NO20033936L NO 20033936 L NO20033936 L NO 20033936L NO 20033936 A NO20033936 A NO 20033936A NO 20033936 A NO20033936 A NO 20033936A NO 20033936 L NO20033936 L NO 20033936L
- Authority
- NO
- Norway
- Prior art keywords
- regulation
- methods
- function
- muscle mass
- factor receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/799,978 US6670140B2 (en) | 2001-03-06 | 2001-03-06 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
PCT/US2002/007476 WO2002069908A2 (en) | 2001-03-06 | 2002-03-06 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20033936D0 NO20033936D0 (no) | 2003-09-05 |
NO20033936L true NO20033936L (no) | 2003-11-05 |
Family
ID=25177205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20033936A NO20033936L (no) | 2001-03-06 | 2003-09-05 | Fremgangsmåter for identifisering av forbindelser for regulering av muskelmasse eller funksjon ved anvendelse avkortikotropinfrigjöringsfaktor-reseptorer |
Country Status (28)
Country | Link |
---|---|
US (3) | US6670140B2 (pt) |
EP (1) | EP1379873B1 (pt) |
JP (2) | JP4331942B2 (pt) |
KR (2) | KR100596991B1 (pt) |
CN (1) | CN100520408C (pt) |
AR (1) | AR032957A1 (pt) |
AT (1) | ATE429242T1 (pt) |
AU (1) | AU2002303121B2 (pt) |
BR (1) | BR0207881A (pt) |
CA (1) | CA2439170C (pt) |
CZ (1) | CZ20032395A3 (pt) |
DE (1) | DE60232063D1 (pt) |
ES (1) | ES2325485T3 (pt) |
HU (1) | HUP0402173A2 (pt) |
IL (1) | IL157330A0 (pt) |
MA (1) | MA26990A1 (pt) |
MX (1) | MXPA03008114A (pt) |
MY (1) | MY134755A (pt) |
NO (1) | NO20033936L (pt) |
NZ (1) | NZ527124A (pt) |
PE (1) | PE20020993A1 (pt) |
PL (1) | PL367187A1 (pt) |
RU (1) | RU2260805C2 (pt) |
SA (1) | SA02230159B1 (pt) |
SK (1) | SK12132003A3 (pt) |
TW (1) | TWI227780B (pt) |
WO (1) | WO2002069908A2 (pt) |
ZA (1) | ZA200305642B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2418144C (en) * | 2000-08-04 | 2013-06-18 | Research Development Foundation | Urocortin proteins and uses thereof |
US20040049009A1 (en) * | 2000-09-22 | 2004-03-11 | Klaus Eckart | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
GB0624282D0 (en) * | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
AU2008255927B2 (en) * | 2007-05-23 | 2012-12-13 | Nippon Chemiphar Co., Ltd. | G-protein-conjugated receptor having altered ligand affinity, and use thereof |
US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
CA3185480A1 (en) * | 2010-12-23 | 2012-06-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
RS56796B1 (sr) * | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
RU2517259C1 (ru) * | 2013-03-06 | 2014-05-27 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) | Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |
JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−1抑制剤 |
RU2568903C2 (ru) * | 2014-04-07 | 2015-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ оценки анаболического действия лекарственных препаратов |
MA49661A (fr) | 2015-04-15 | 2020-06-03 | Regeneron Pharma | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
WO2018075973A2 (en) * | 2016-10-20 | 2018-04-26 | Cortene Inc. | Methods of treating diseases resulting from a maladapted stress response |
CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415558A (en) * | 1981-06-08 | 1983-11-15 | The Salk Institute For Biological Studies | CRF And analogs |
US4533654A (en) * | 1982-09-29 | 1985-08-06 | The Salk Institute For Biological Studies | Urotensin peptides |
US4489163A (en) * | 1983-04-14 | 1984-12-18 | The Salk Institute For Biological Studies | rCRF and analogs |
US4594329A (en) * | 1984-05-14 | 1986-06-10 | The Salk Institute For Biological Studies | CRF analogs |
US4605642A (en) * | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
DE3703340A1 (de) * | 1987-02-04 | 1988-08-18 | Dirck Dr Med Oppermann | Pharmazeutische zubereitung zur behandlung der herzinsuffizienz |
US4908352A (en) * | 1987-09-28 | 1990-03-13 | The Salk Institute For Biological Studies | Urotensin peptides |
US5109111A (en) * | 1988-09-23 | 1992-04-28 | The Salk Institute For Biological Studies | CRF antagonists |
US5278146A (en) * | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
CA1340964C (en) * | 1988-09-30 | 2000-04-18 | Jean E. F. Rivier | Crf analogs |
US5235036A (en) | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
US5493006A (en) * | 1993-06-16 | 1996-02-20 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
US5728545A (en) * | 1993-06-18 | 1998-03-17 | The Salk Institute Of Biological Studies | Cloning and recombinant production of CRF receptor (S) |
US6495343B1 (en) * | 1993-06-18 | 2002-12-17 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
EP0860501A3 (en) | 1994-06-14 | 1999-05-19 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
ATE171212T1 (de) * | 1994-06-14 | 1998-10-15 | Neurocrine Biosciences Inc | Corticotropin freisetzende rezeptoren des faktor 2 |
US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
US5824771A (en) | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
US5663292A (en) | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
CA2223792A1 (en) | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
US5869450A (en) | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
US5888811A (en) * | 1996-05-23 | 1999-03-30 | Dupont Pharmaceuticals Company | Corticotropin-releasing hormone receptor |
CA2338561A1 (en) * | 1998-07-24 | 2000-02-03 | Joachim Spiess | Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2) |
CA2418144C (en) * | 2000-08-04 | 2013-06-18 | Research Development Foundation | Urocortin proteins and uses thereof |
US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-03-06 US US09/799,978 patent/US6670140B2/en not_active Expired - Lifetime
-
2002
- 2002-03-05 PE PE2002000176A patent/PE20020993A1/es not_active Application Discontinuation
- 2002-03-05 TW TW091104025A patent/TWI227780B/zh not_active IP Right Cessation
- 2002-03-06 MX MXPA03008114A patent/MXPA03008114A/es active IP Right Grant
- 2002-03-06 NZ NZ527124A patent/NZ527124A/en unknown
- 2002-03-06 MY MYPI20020802A patent/MY134755A/en unknown
- 2002-03-06 BR BR0207881-3A patent/BR0207881A/pt not_active IP Right Cessation
- 2002-03-06 JP JP2002569086A patent/JP4331942B2/ja not_active Expired - Fee Related
- 2002-03-06 RU RU2003129500/15A patent/RU2260805C2/ru not_active IP Right Cessation
- 2002-03-06 SK SK1213-2003A patent/SK12132003A3/sk unknown
- 2002-03-06 AT AT02731122T patent/ATE429242T1/de not_active IP Right Cessation
- 2002-03-06 HU HU0402173A patent/HUP0402173A2/hu unknown
- 2002-03-06 CN CNB028059271A patent/CN100520408C/zh not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011659A patent/KR100596991B1/ko not_active IP Right Cessation
- 2002-03-06 CA CA2439170A patent/CA2439170C/en not_active Expired - Fee Related
- 2002-03-06 ES ES02731122T patent/ES2325485T3/es not_active Expired - Lifetime
- 2002-03-06 DE DE60232063T patent/DE60232063D1/de not_active Expired - Lifetime
- 2002-03-06 AU AU2002303121A patent/AU2002303121B2/en not_active Ceased
- 2002-03-06 IL IL15733002A patent/IL157330A0/xx unknown
- 2002-03-06 CZ CZ20032395A patent/CZ20032395A3/cs unknown
- 2002-03-06 AR ARP020100806A patent/AR032957A1/es not_active Application Discontinuation
- 2002-03-06 EP EP02731122A patent/EP1379873B1/en not_active Expired - Lifetime
- 2002-03-06 PL PL02367187A patent/PL367187A1/xx not_active Application Discontinuation
- 2002-03-06 WO PCT/US2002/007476 patent/WO2002069908A2/en active IP Right Grant
- 2002-03-06 KR KR1020067005678A patent/KR100598441B1/ko not_active IP Right Cessation
- 2002-06-19 SA SA02230159A patent/SA02230159B1/ar unknown
-
2003
- 2003-07-22 ZA ZA200305642A patent/ZA200305642B/en unknown
- 2003-08-07 MA MA27267A patent/MA26990A1/fr unknown
- 2003-08-27 US US10/649,852 patent/US7063954B2/en not_active Expired - Lifetime
- 2003-09-05 NO NO20033936A patent/NO20033936L/no not_active Application Discontinuation
-
2006
- 2006-04-26 US US11/412,025 patent/US7572768B2/en not_active Expired - Fee Related
-
2008
- 2008-09-01 JP JP2008224143A patent/JP2009029816A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20033936D0 (no) | Fremgangsmåter for identifisering av forbindelser for regulering av muskelmasse eller funksjon ved anvendelse avkortikotropinfrigjöringsfaktorreseptorer | |
PT1312922E (pt) | Composicoes de reagente de tetrazolio estabilizadas com nitrito e metodos para a utilizacao das mesmas | |
DK1427437T3 (da) | Oxyntomodulin til forebyggelse eller behandling af overvægt | |
DK1446122T5 (da) | Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften | |
DK1546122T3 (da) | Fremgangsmåde til fremstilling af valsartan | |
DE60214725D1 (de) | Verfahren zur bestimmung der expression des dihydropyrimidindehydrogenasegens | |
ATE370922T1 (de) | Verfahren zur gewichtsverminderung von gipsbauplatten | |
NO20031898D0 (no) | Gjensidig forbindbare paneler ved nedsenkning | |
PL371297A1 (en) | Method of treating depression with delta receptor agonist compounds | |
DK1474689T3 (da) | Fremgangsmåde til diagnosticering af inflammatoriske sygdomme ved anvendelse af calgranulin c | |
EE05247B1 (et) | Meetod imidasoolhendite valmistamiseks | |
DE60321098D1 (de) | Verfahren zur Herstellung von Hydroxyalkyl(meth)acrylat | |
DK1575941T3 (da) | Fremgangsmåde til fremstilling af (S)-pantoprazol | |
NO20031807L (no) | Fremgangsmåter for identifisering av forbindelser fra regulering av muskelmasse eller funksjon ved anvendelse av vasoaktivetarmpeptidreseptorer | |
ITMI992319A0 (it) | Metodo per la determinazione qualitativa e quantitativa di anticorpi u mani di classe igc | |
IL173162A0 (en) | Methods for identifying compounds for regulating muscle mass or function using dopamine receptors | |
NO20015491D0 (no) | Anordning for bruk ved elektrolyttisk fremstilling av aluminium | |
ZA200602603B (en) | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | |
DK1392711T3 (da) | Fremgangsmåde til fremstilling af xylose | |
NO20043935L (no) | Fremgangsmåte ved fremstilling av interferon | |
NO20033819L (no) | Fremgangsmåte ved regulering av elektrolysecelle | |
NO20042116L (no) | Avgiftning av oniumforbindelser | |
SI1622926T1 (sl) | Nov postopek in intermediati za pripravo 17-halogen-19-nor-steroidnih spojin | |
DE50307920D1 (de) | Wasser-in-Öl-Cremes von Organo-Siliciumverbindungen | |
DE10158147A8 (de) | Verfahren zur Bestimmung von Autoantikörpern gegen oxidierte LDL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |